Loïc Badé will join Bayer Leverkusen if nothing goes wrong in the coming hours, according to Spanish journalist Alejandro Sáez. Fabrizio Romano also notes that Badé is very close to leaving Sevilla ...

Kumquat, based in San Diego, received US Food and Drug Administration clearance of its investigational new drug application for the KRAS G12D inhibitor in July. The firm will be responsible for ...

Serie A Defender on the RadarThe summer transfer window is always a pivotal time for football clubs, and Liverpool are ...

Small bands of Russian soldiers thrust deeper into eastern Ukraine on Tuesday ahead of a summit this week between Russian ...

Cristiano Ronaldo demanded a contract clause to return to Manchester United in 2021 and it's one that could cost Chelsea in the future ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

Liverpool have no intention to sell Ibrahima Konate this window despite working on moves for two centre backs, as they ...

Liverpool are keen on continuing their summer transfer spending spree with a swoop for England international Marc Guehi ...

MANCHESTER UNITED are in for an absolutely massive summer of transfer business at Old Trafford! The Red Devils reportedly ...

German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US-based biotech company to develop its prospective cancer drug.

Today’s White House MAHA Commission report is expected to pull punches on pesticide regulation as Bayer lobbies to limit ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...